AI Article Synopsis
- Harlequin ichthyosis (HI) is a serious condition linked to high mortality rates.
- Early treatment with systemic retinoids is common but its effectiveness is still debated.
- Two newborns with severe mutations associated with HI survived and were discharged without using systemic retinoids, thanks to intensive care.
Article Abstract
Harlequin ichthyosis (HI) is associated with high mortality. Early systemic retinoids are widely used, although their use remains debatable. We reported two neonates with homozygous mutations in ABCA12 consistent with harlequin ichthyosis who survived to discharge home with intensive care and without use of systemic retinoids.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pde.13770 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Congenital Bilateral Ectropion in Collodion Infants: A Case Series.
Cureus
November 2024
Ophthalmology, Regional Institute of Ophthalmology, Indira Gandhi Institute of Medical Sciences, Patna, Patna, IND.
Collodion baby is a rare congenital condition marked by a parchment-like membrane covering the body, often leading to complications such as bilateral ectropion. This condition poses risks of exposure keratopathy and other ocular issues. We present a case series of five infants with congenital bilateral ectropion associated with collodion babies, all born prematurely.
View Article and Find Full Text PDFProtean Cutaneous Manifestation Caused by ABCA12 variants: Erythrokeratodermia Variabilis-like Ichthyosis and Unique Palmoplantar Keratoderma.
Clin Exp Dermatol
November 2024
Department of Dermatology, National Cheng Kung University Hospital, Tainan, Taiwan.
ABCA12 is crucial for skin barrier function and traditionally linked to severe congenital ichthyosis, such as harlequin ichthyosis. However, its genotype-phenotype relationship may be more nuanced. Using whole-exome sequencing and Sanger sequencing, we identified four cases of mild ichthyosis with biallelic ABCA12 pathogenic variants.
View Article and Find Full Text PDFTralokinumab and Acitretin for the Treatment of Lamellar Ichthyosis.
JAMA Dermatol
December 2024
Department of Dermatology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
Harlequin Ichthyosis Nanobubble Hydrotherapy: A Breakthrough in Treatment.
Cureus
September 2024
Dermatology, Al Dhannah Hospital, Abu Dhabi, ARE.
Article Synopsis
- This case report focuses on a 10-year-old girl with Harlequin ichthyosis, a severe skin condition that causes excessive skin growth and fissures, making traditional treatments ineffective.
- The introduction of nanobubble technology during a 100-hour medical trial at a dermatologist's office led to noticeable improvements in her skin condition after just one session.
- The success of this treatment spurred the founding of the White Water Company to create portable nanobubblers, which not only help manage the skin symptoms but also improve biofilm remediation, offering a comprehensive solution for the patient.
A cellular disease model toward gene therapy of -dependent lamellar ichthyosis.
Mol Ther Methods Clin Dev
September 2024
Center for Regenerative Medicine "Stefano Ferrari", Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Lamellar ichthyosis (LI) is a chronic disease, mostly caused by mutations in the gene, marked by impaired skin barrier formation. No definitive therapies are available, and current treatments aim at symptomatic relief. LI mouse models often fail to faithfully replicate the clinical and histopathological features of human skin conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!